Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study
Risk of major adverse cardiovascular events in patients initiating biologics/apremilast …
Risk of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis initiating interleukin 17 inhibitors: a nationwide population-based study using the French national health data system
Background Sex differences in phenotype presentation, disease trajectory and treatment …